IP Library Granted Patent US 12,594,328
Granted Patent B2
US 12,594,328 · App. 17/918,006 · Granted Apr 7, 2026

Combination of vaccines to prophylactically treat a pig

Inventors: Maarten Hendrik Witvliet (Oostrum, NL); Jacquelyn Horsington (Nijmegen, NL)
Assignee: Intervet Inc.
A61K39/12A61K39/0241A61K39/295A61P31/04A61P31/20C12N7/00A61K2039/522A61K2039/5254A61K2039/54A61K2039/545A61K2039/552A61K2039/70C12N2750/00022C12N2750/10021C12N2750/10034C12N2750/10062C12N2750/10071
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,594,328
App. No.
17/918,006
Granted
Apr 7, 2026
Kind
B2
Abstract

The invention pertains to a combination of a first vaccine comprising anon-replicating immunogen of porcine circovirus type 2 (PCV-2) and a non-replicating immunogen of Mycoplasma hyopneumoniae , and a second vaccine comprising a live attenuated porcine reproductive and respiratory syndrome (PRRS) virus, for use in prophylactically treating a pig against an infection with PCV-2, an infection with Mycoplasma hyopneumoniae and an infection with PRRS virus, by associated separate injection of the first vaccine and the second vaccine into a tissue of the pig at a first and a second injection site respectively, wherein the first and second injection sites are at most 5 cm apart from each other.

Claims (9)

1 . A method of prophylactically treating a pig against an infection with porcine circovirus type 2 (PCV2), an infection with Mycoplasma hyopneumoniae and an infection with PRRS virus by injecting into a tissue of the pig at a first and a second injection site respectively, an associated separate injection of a first vaccine comprising a non-replicating immunogen of porcine circo virus type 2 (PCV2) and a non-replicating immunogen of Mycoplasma hyopneumoniae , and a second vaccine comprising a live attenuated porcine reproductive and respiratory syndrome (PRRS) virus; wherein the associated separate injection of the first vaccine and the second vaccine occur simultaneously, and wherein the first and second injection sites are at most 5 cm apart from each other.

2 . The method of prophylactically treating of claim 1 , wherein the first and second injection sites are at most 4 cm apart from each other.

3 . The method of prophylactically treating of claim 2 , wherein the first and second injection sites are at most 3 cm apart from each other.

4 . The method of prophylactically treating of claim 1 , wherein the first and second vaccine through said injection are deposited at least partly into muscular tissue of the pig.

5 . The method of prophylactically treating of claim 4 , wherein the first and second vaccine are injected either by a hypodermic syringe that extends into the muscular tissue or by a jet stream of the respective vaccines using a needle-less device, wherein the jet stream penetrates the skin of the pig.

6 . The method of prophylactically treating of claim 1 , wherein the first vaccine and the second vaccine are administered by a single dose.

7 . The method of prophylactically treating of claim 1 , wherein the non-replicating immunogen of PCV2 is recombinantly expressed protein encoded by the ORF2 gene of PCV2.

8 . The method of prophylactically treating of claim 7 , wherein the non-replicating immunogen of PCV2 is baculovirus expressed protein of PCV2.

9 . The method of prophylactically treating of claim 1 , wherein the non-replicating immunogen of Mycoplasma hyopneumoniae is a Mycoplasma hyopneumoniae bacterin.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2024
From: HORSINGTON, JACQUELYN; WITVLIET, MAARTEN HENDRIK
To: INTERVET INTERNATIONAL B.V.
Reel/Frame 069605/0530 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2024
From: INTERVET INTERNATIONAL B.V.
To: INTERVET INC.
Reel/Frame 069605/0818 →
CHANGE OF ADDRESS Recorded Sep 26, 2023
From: INTERVET INC.
To: INTERVET INC.
Reel/Frame 065028/0818 →
Priority Claims (1)
EP 20170442 · Apr 20, 2020 · regional
Continuity (1)
Related Publication 20230338500A1 · Oct 26, 2023
References Cited (17)
US 20200046825A1 · Witvliet et al. · 2020 [cited by applicant]
JP 2017523139A · 2017 [cited by applicant]
JP 2019509300A · 2019 [cited by applicant]
WO 2015189425A1 · 2015 [cited by applicant]
WO 2017162741A1 · 2017 [cited by applicant]
WO 2018189290A1 · 2018 [cited by applicant]
Nakano, Takashi, Hearing on the PDCA Cycle in the Basic Plan for Vaccinations: ‘Simultaneous Administration and Administration Intervals’, 18th Meeting of the Health Sciences Council, N/A, Slide 14, 2017 (English transl… [cited by applicant]
Charerntantanakul, Wasin et al., Co-administration of saponin quil A and PRRSV-1 modified-live virus vaccine up-regulates gene expression of type I interferon-regulated gene, type I and II interferon, and inflammatory c… [cited by applicant]
Dolan, Samantha B. et al., Administering Multiple Injectable Vaccines During a Single Visit—Summary of Findings From the Accelerated Introduction of Inactivated Polio Vaccine Globally, The Journal of Infectious Diseases… [cited by applicant]
Kharkevich, D.A., Pharmacology, Moscow: GEOTAR-Media, 10th Edition, 73-74, 2010. [cited by applicant]
Kharkevich, D.A., Pharmacology, Moscow: GEOTAR-Media, Textbook for HS, 10th Ed., 73-74, 2010. [cited by applicant]
Oh, Taehwan et al., Evaluation of the efficacy of a trivalent vaccine mixture against a triple challenge with Mycoplasma hyopneumoniae, PCV2, and PRRSV and the efficacy comparison of the respective monovalent vaccines a… [cited by applicant]
Svistunov, A.A., et al., Pharmacology: Textbook, M.: Laboratory of Knowledge, N/A, 55-56, 2017. [cited by applicant]
Department Of Health: “Immunization Program”, Dec. 1, 2018 (Dec. 1, 2018), XP055732044, Retrieved from the Internet: URL: https ://www. health.state.mn.us/people/immunize/hcp/admim.pdf[retrieved on Sep. 18, 2020], 2 pag… [cited by applicant]
Dolan, Samantha et al., Summary of evidence on the administration of multiple injectable vaccines in infants during a single visit: safety, immunogenicity, and vaccine administration practices, Apr. 2015 SAGE Meeting, 2… [cited by applicant]
Ruansit, Wilawan et al., 0ral supplementation of quercetin in PRRSV-1 modified-live virus vaccinated pigs in response to HP-PRRSV-2 challenge, Vaccine, 2020, 3570-3581, 38(19). [cited by applicant]
Saskatchewan: “Saskatchewan Immunization Manual Chapter 8—Administration of Biological Products”, Jun. 1, 2018 (Jun. 1, 2018), XP55732030, Retrieved from the Internet:URL: https://www.ehealthsask.ca/services/Manuals/Doc… [cited by applicant]